Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SELECT

SELECT

Semaglutide · Obesity + established CVD, no diabetes

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
Obesity + established CVD, no diabetes
Official title
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2018-10 → 2023-06
Participants
17604
Registry
NCT03574597

Cardiovascular and kidney outcomes

SELECT semaglutide 2.4 mg vs placebo · Obesity + established CVD, no diabetes · n = 17604 · 2023 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
Primary composite: CV death, nonfatal MI, or nonfatal stroke (time to first event)
0.800.72–0.90569 vs 701verified
Cardiovascular death
Death from cardiovascular causes (first confirmatory secondary endpoint)
0.850.71–1.01223 vs 262verified
All-cause death
Death from any cause (third confirmatory secondary endpoint)
0.810.71–0.93375 vs 458verified
Myocardial infarction
Nonfatal myocardial infarction only (supportive secondary endpoint); fatal MI not reported separately
0.720.61–0.85234 vs 322verified
Stroke
Nonfatal stroke only (supportive secondary endpoint); fatal stroke not reported separately
0.930.74–1.15154 vs 165verified
Hospitalisation for heart failure
Hospitalization or urgent medical visit for heart failure (supportive secondary endpoint)
0.790.60–1.0397 vs 122verified
CV death or worsening HF
Heart failure composite: CV death or hospitalization or urgent medical visit for heart failure (second confirmatory secondary endpoint)
0.820.71–0.96300 vs 361verified
Kidney composite
Nephropathy composite (supportive secondary): renal death, long-term renal replacement therapy, persistent eGFR <15, persistent 50% eGFR reduction, or persisten
0.780.63–0.96155 vs 198verified
Expanded MACE (MACE + revasc. + UA)
Cardiovascular expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina leading to hospitalization
0.800.73–0.87873 vs 1074verified
New-onset diabetes
Glycated hemoglobin level >=6.5% (glycemic threshold for diabetes) in a population without diabetes at baseline; patients randomized in error with baseline HbA1c >6.5% excluded (8800 vs 8797 analysed)
0.270.24–0.31306 vs 1059verified
Coronary revascularisation
Coronary revascularization
0.770.68–0.87473 vs 608verified
Hospitalisation for unstable angina
Unstable angina leading to hospitalization
0.870.67–1.13109 vs 124verified
Verbatim quotes (12)
  • 3-point MACE · Results, Efficacy End Points; Table 2
    occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval [CI], 0.72 to 0.90
  • Cardiovascular death · Results, Efficacy End Points; Table 2
    occurred in 223 patients (2.5%) in the semaglutide group and in 262 patients (3.0%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.71 to 1.01; P=0.07
  • All-cause death · Table 2
    Death from any cause | 375 (4.3) | 458 (5.2) | 0.81 (0.71 to 0.93)
  • Myocardial infarction · Table 2
    Nonfatal myocardial infarction | 234 (2.7) | 322 (3.7) | 0.72 (0.61 to 0.85)
  • Stroke · Table 2
    Nonfatal stroke | 154 (1.7) | 165 (1.9) | 0.93 (0.74 to 1.15)
  • Hospitalisation for heart failure · Table 2
    Hospitalization or urgent medical visit for heart failure | 97 (1.1) | 122 (1.4) | 0.79 (0.60 to 1.03)
  • CV death or worsening HF · Table 2
    Heart failure composite end point§ | 300 (3.4) | 361 (4.1) | 0.82 (0.71 to 0.96)
  • Kidney composite · Table 2
    Nephropathy composite end point‖‖ | 155 (1.8) | 198 (2.2) | 0.78 (0.63 to 0.96)
  • Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary end points
    | Cardiovascular expanded composite end point∥ | 873 (9.9) | 1074 (12.2) | 0.80 (0.73 to 0.87) | NA |
  • New-onset diabetes · Table 2, supportive secondary end points
    | Glycated hemoglobin level ≥6.5%†† | 306 (3.5) | 1059 (12.0) | 0.27 (0.24 to 0.31) | NA |
  • Coronary revascularisation · Table 2, supportive secondary end points
    | Coronary revascularization | 473 (5.4) | 608 (6.9) | 0.77 (0.68 to 0.87) | NA |
  • Hospitalisation for unstable angina · Table 2, supportive secondary end points
    | Unstable angina leading to hospitalization | 109 (1.2) | 124 (1.4) | 0.87 (0.67 to 1.13) | NA |

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SELECT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/select/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.